Lili Barsky1, Chrisandra Shufelt1, Marie Lauzon1, B Delia Johnson2, Sarah L Berga3, Glenn Braunstein1, Vera Bittner4, Leslee Shaw5, Steven Reis2, Eileen Handberg6, Carl J Pepine6, C Noel Bairey Merz1. 1. Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, California, USA. 2. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 3. Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, USA. 4. Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. 5. Dalio Institute of Cardiovascular Imaging, Weill Cornell Medicine and New York-Presbyterian Hospital, New York, New York, USA. 6. Division of Cardiology, Department of Medicine, University of Florida, Gainesville, Florida, USA.
Abstract
Background: Previous Women's Ischemia Syndrome Evaluation (WISE) work demonstrated prior oral contraceptive (OC) use was associated with lower coronary artery disease (CAD) in women with suspected ischemia. The association of prior OC use with longer term all-cause and cardiovascular disease (CVD) mortality is unclear. Materials and Methods: WISE women undergoing coronary angiography for suspected ischemia (enrolled 1996-2001) with prior OC use history and 10-year follow-up data were analyzed. A blinded core laboratory assessed atherosclerotic CAD severity. Kaplan-Meier analyses evaluated prior OC use relative to all-cause and CVD mortality. Cox regression analyses adjusted for baseline differences. Mediation, interaction, and multicollinearity were analyzed. Results: Our 686 women had a mean age 62.5 ± 9.6 years, multiple cardiac risk factors, and 39% previously used OC. Prior OC users were younger, with less lipid-lowering medication use and lower atherosclerotic CAD severity scores (all p < 0.05). Prior OC use was associated with lower 10-year all-cause (p = 0.007) and CVD mortality (p = 0.019). After adjustment, this was no longer significant (p = 0.77 and p = 0.90, respectively). Atherosclerotic CAD severity score mediated one-third of the observed association. Prior OC use was associated with increased CVD mortality among women with very elevated menopausal systolic blood pressure (SBP). Conclusions: Unadjusted prior OC use was associated with lower longer-term all-cause and CVD mortality. One-third of this observed effect appears mediated by the atherosclerotic CAD severity score. Prior OC was adversely associated with CVD mortality in women with very elevated menopausal SBP. Additional investigation is needed to understand the potential benefits and harms of prior OC use. Clinical Trial Number: NCT00000554, or https://www.clinicaltrials.gov/ct2/show/NCT00000554.
Background: Previous Women's Ischemia Syndrome Evaluation (WISE) work demonstrated prior oral contraceptive (OC) use was associated with lower coronary artery disease (CAD) in women with suspected ischemia. The association of prior OC use with longer term all-cause and cardiovascular disease (CVD) mortality is unclear. Materials and Methods: WISE women undergoing coronary angiography for suspected ischemia (enrolled 1996-2001) with prior OC use history and 10-year follow-up data were analyzed. A blinded core laboratory assessed atherosclerotic CAD severity. Kaplan-Meier analyses evaluated prior OC use relative to all-cause and CVD mortality. Cox regression analyses adjusted for baseline differences. Mediation, interaction, and multicollinearity were analyzed. Results: Our 686 women had a mean age 62.5 ± 9.6 years, multiple cardiac risk factors, and 39% previously used OC. Prior OC users were younger, with less lipid-lowering medication use and lower atherosclerotic CAD severity scores (all p < 0.05). Prior OC use was associated with lower 10-year all-cause (p = 0.007) and CVD mortality (p = 0.019). After adjustment, this was no longer significant (p = 0.77 and p = 0.90, respectively). Atherosclerotic CAD severity score mediated one-third of the observed association. Prior OC use was associated with increased CVD mortality among women with very elevated menopausal systolic blood pressure (SBP). Conclusions: Unadjusted prior OC use was associated with lower longer-term all-cause and CVD mortality. One-third of this observed effect appears mediated by the atherosclerotic CAD severity score. Prior OC was adversely associated with CVD mortality in women with very elevated menopausal SBP. Additional investigation is needed to understand the potential benefits and harms of prior OC use. Clinical Trial Number: NCT00000554, or https://www.clinicaltrials.gov/ct2/show/NCT00000554.
Authors: S E Reis; R Holubkov; A J Conrad Smith; S F Kelsey; B L Sharaf; N Reichek; W J Rogers; C N Merz; G Sopko; C J Pepine Journal: Am Heart J Date: 2001-05 Impact factor: 4.749
Authors: Jean-Patrice Baillargeon; Donna K McClish; Paulina A Essah; John E Nestler Journal: J Clin Endocrinol Metab Date: 2005-04-06 Impact factor: 5.958
Authors: C Noel Bairey Merz; B Delia Johnson; Sarah Berga; Glenn Braunstein; Steven E Reis; Vera Bittner Journal: Fertil Steril Date: 2006-04-05 Impact factor: 7.329
Authors: C Noel Bairey Merz; B Delia Johnson; Sarah L Berga; Glenn D Braunstein; Ricardo Azziz; Yuching Yang; Steven E Reis; Vera Bittner; T Keta Hodgson; Carl J Pepine; Barry L Sharaf; George Sopko; Sheryl F Kelsey Journal: J Womens Health (Larchmt) Date: 2009-09 Impact factor: 2.681
Authors: Tara A Seibert; Benjamin Hibbert; Yong-Xiang Chen; Katey Rayner; Trevor Simard; Tieqiang Hu; Charles M Cuerrier; Xiaoling Zhao; Jacqueline de Belleroche; Benjamin J W Chow; Steven Hawken; Kumanan R Wilson; Edward R O'Brien Journal: J Am Coll Cardiol Date: 2013-06-10 Impact factor: 24.094
Authors: Virginia M Miller; Fredrick Naftolin; Sanjay Asthana; Dennis M Black; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; N Maritza Dowling; Carey E Gleason; Howard N Hodis; Muthuvel Jayachandran; Kejal Kantarci; Rogerio A Lobo; JoAnn E Manson; Lubna Pal; Nanette F Santoro; Hugh S Taylor; S Mitchell Harman Journal: Menopause Date: 2019-09 Impact factor: 2.953